Jardiance: How to Safely Stop Empagliflozin

How Empagliflozin Works: The Mechanism That Makes Stopping Complicated

Empagliflozin selectively inhibits sodium-glucose cotransporter 2 (SGLT2) in the proximal tubule of the kidney, blocking roughly 30 to 50 percent of filtered glucose from being reabsorbed. The result is urinary glucose excretion of approximately 70 to 80 grams per day in patients with type 2 diabetes at the 10 mg dose. FDA prescribing information confirms this mechanism and the downstream hemodynamic effects, including a drop in systolic blood pressure of roughly 3 to 4 mmHg and a reduction in body weight of 2 to 3 kg over 26 weeks.

SGLT2 Inhibition Beyond Glucose

The drug does far more than lower blood sugar. By driving glycosuria, it creates an osmotic diuresis that reduces plasma volume and cardiac preload. This mechanism is why EMPA-REG OUTCOME, a cardiovascular outcomes trial in 7,020 patients with type 2 diabetes and established cardiovascular disease, found a 38 percent relative risk reduction in cardiovascular death compared with placebo at a median follow-up of 3.1 years (Zinman et al., NEJM 2015). That trial also recorded a 35 percent reduction in hospitalization for heart failure.

What Reverses When You Stop

Each of these hemodynamic and metabolic changes is reversible. Within 3 to 7 days of stopping empagliflozin, urinary glucose excretion returns to baseline, plasma volume expands, and glycated hemoglobin begins to climb. A 2019 analysis in Diabetes Care documented HbA1c increases of 0.6 to 1.2 percentage points within 12 weeks of SGLT2 inhibitor discontinuation in patients not bridged to another agent. Clinicians must anticipate this trajectory.

Why You Cannot Simply Stop Without a Plan

Abrupt discontinuation is not dangerous in the way opioid or benzodiazepine withdrawal is, but it carries three specific clinical risks that require proactive management.

Risk 1: Glycemic Rebound

Patients with type 2 diabetes who stop empagliflozin without a bridge agent lose roughly 70 to 80 grams of daily glucose disposal through the kidney (FDA label). Fasting plasma glucose can rise by 20 to 40 mg/dL within a week. For patients already near the upper boundary of glycemic targets set by the American Diabetes Association (HbA1c below 7.0 percent for most non-pregnant adults), this rebound may push them out of goal range before their next scheduled visit (ADA Standards of Care 2024).

Risk 2: Euglycemic Diabetic Ketoacidosis

SGLT2 inhibitors shift fuel metabolism toward ketone oxidation. During this shift, plasma ketones rise even while blood glucose remains below 250 mg/dL, a phenomenon called euglycemic DKA. The FDA added a black-box warning for DKA in 2015 covering all drugs in this class. The risk does not vanish the moment the last tablet is swallowed. Because empagliflozin has a half-life of approximately 12.4 hours, significant SGLT2 inhibition persists for up to 72 hours post-dose. Any patient who develops nausea, vomiting, or abdominal pain in that window should have ketones checked even if their glucometer reads normal.

Risk 3: Loss of Organ Protection

For patients taking empagliflozin under the heart failure or CKD indication, stopping removes a therapy with documented mortality benefit. The EMPEROR-Reduced trial (N=3,730) showed empagliflozin reduced the composite of CV death or hospitalization for heart failure by 25 percent versus placebo (Packer et al., NEJM 2020). The EMPEROR-Preserved trial (N=5,988) extended this finding to heart failure with preserved ejection fraction (Anker et al., NEJM 2021). Stopping empagliflozin in a patient with heart failure without substituting an alternative SGLT2 inhibitor or adjusting diuretic therapy is a decision that requires explicit cardiologist input.

The Step-by-Step Discontinuation Protocol

This framework reflects FDA prescribing guidance, the 2024 ADA Standards of Care, and published perioperative SGLT2 inhibitor protocols. Your prescriber may adjust it based on your specific clinical picture.

Step 1: Identify the Reason for Stopping

The reason shapes the entire plan.

• Elective surgery: The FDA label and the 2023 joint statement from the American Diabetes Association and European Association for the Study of Diabetes recommend withholding empagliflozin at least 3 days before any elective procedure requiring general, neuraxial, or deep sedation anesthesia. Some anesthesia societies extend this to 4 days. This recommendation exists because perioperative fasting plus surgical stress dramatically raises euglycemic DKA risk (Schöpp et al., Diabetes Care 2021).
• Adverse effect: Recurrent genital mycotic infections (reported in 5.4 percent of women in EMPA-REG OUTCOME vs. 1.5 percent placebo) or urinary tract infections may prompt discontinuation. These cases need immediate glycemic bridging but carry lower acute safety risk than perioperative scenarios.
• Renal impairment: Empagliflozin has reduced glycemic efficacy when eGFR falls below 45 mL/min/1.73 m² and is generally stopped when eGFR drops below 20 mL/min/1.73 m² for the diabetes indication, though the cardiorenal indication may be continued per updated labeling (FDA label 2023).
• Pregnancy: Stop immediately. SGLT2 inhibitors are contraindicated in the second and third trimesters due to fetal renal toxicity. Insulin becomes the standard of care (ACOG Practice Bulletin).

Step 2: Arrange the Bridge Before the Last Dose

Do not stop first and figure out replacement later. The glycemic bridge should be in place on the same day or the day before the last empagliflozin dose.

Common bridging options by indication:

| Indication | Typical Bridge | |---|---| | T2D, on metformin | Continue metformin; consider adding sulfonylurea or DPP-4 inhibitor | | T2D, on insulin | Increase basal insulin dose by 10 to 20 percent; monitor glucose twice daily | | Heart failure only | Consult cardiology; adjust diuretic dose; consider dapagliflozin if switching | | CKD (non-diabetic) | Consult nephrology; consider dapagliflozin; monitor blood pressure closely |

Step 3: Stop the Tablet. No Taper Required.

Empagliflozin does not require a pharmacologic taper. Halving the dose from 25 mg to 10 mg provides no clinical benefit in terms of reducing DKA risk or softening the glycemic rebound, because both 10 mg and 25 mg produce near-maximal SGLT2 inhibition. Take the last full prescribed dose, then stop.

Step 4: The 72-Hour Watch Window

For the first three days after the last tablet, patients should monitor for:

• Nausea, vomiting, or abdominal pain
• Unusual fatigue
• Difficulty breathing
• Any of these symptoms warrant a blood ketone check, not just a finger-stick glucose. A beta-hydroxybutyrate level above 1.0 mmol/L in the setting of these symptoms is an emergency.

Patients who are fasting for surgery during this window should have IV dextrose-containing fluids started promptly by the anesthesia team to prevent ketosis.

Step 5: Glucose Monitoring After the Bridge Is Established

Check fasting blood glucose daily for the first week. If HbA1c was at or near target before stopping, a 0.5 to 1.0 percentage point rise may push the patient out of range. An in-person or telehealth visit at 4 weeks post-discontinuation to review HbA1c trajectory is appropriate. The ADA recommends HbA1c testing at least twice yearly in patients with stable glycemic control and quarterly when therapy changes (ADA Standards 2024).

Special Populations: Adjustments to the Protocol

Patients With Type 1 Diabetes (Off-Label Use)

Empagliflozin is not FDA-approved for type 1 diabetes, but some patients receive it off-label. The DKA risk in type 1 is substantially higher than in type 2, with rates in clinical trials reaching 4 to 5 percent annually (Dandona et al., Diabetes Care 2018). These patients should hold empagliflozin at least 4 to 5 days before surgery and should check blood ketones daily during the discontinuation window, not just if symptomatic.

Patients on RAAS Inhibitors or Diuretics

Empagliflozin has a diuretic-like effect. Stopping it while continuing an ACE inhibitor, ARB, or loop diuretic at unchanged doses may cause less diuresis than expected, and some patients with heart failure may experience fluid retention within 1 to 2 weeks. Loop diuretic doses may need upward adjustment. Cardiology or nephrology review is appropriate for anyone on three or more antihypertensive agents.

Elderly Patients (Age 75 and Older)

Older adults tolerate the osmotic diuresis of SGLT2 inhibitors less predictably. On the flip side, stopping empagliflozin in this group may trigger a modest rise in blood pressure (3 to 4 mmHg systolic) and fluid retention. Monitor weight and blood pressure weekly for the first two weeks after stopping.

What Happens to Cardiovascular and Renal Benefits After Stopping?

This is the question most patients do not think to ask. The EMPA-REG OUTCOME data show sustained separation of the Kaplan-Meier curves for CV death throughout the 3.1-year follow-up period, with a hazard ratio of 0.62 (95% CI 0.49 to 0.77, P<0.001) for cardiovascular death (Zinman et al., NEJM 2015). What the trial cannot tell us is how quickly that benefit erodes after stopping, because it was not designed for that question.

Observational data from registry analyses suggest the hemodynamic and natriuretic effects reverse within 1 to 4 weeks. The atheroprotective or anti-inflammatory effects, if any exist independently of glucose and pressure, may take longer to reverse. The practical implication: if a patient stops empagliflozin permanently for a non-urgent reason, the prescriber should document a plan for restarting or substituting an evidence-based alternative within a defined timeframe, typically 30 to 90 days.

Renal Decline After Stopping

The EMPA-KIDNEY trial (N=6,609) demonstrated that empagliflozin reduced the risk of kidney disease progression or cardiovascular death by 28 percent in patients with CKD (The EMPA-KIDNEY Collaborative Group, NEJM 2023). After stopping empagliflozin, eGFR typically rises slightly in the short term (due to reversal of the glomerular hemodynamic effect), then may trend back toward the patient's underlying slope of decline. Nephrology follow-up within 60 days is appropriate for any CKD patient who stops empagliflozin permanently.

Can Empagliflozin Be Restarted After Stopping?

Yes, in most cases. Restart at the original dose once the reason for stopping has resolved. For post-surgical patients, the FDA label and multiple anesthesia society guidelines recommend waiting until the patient is eating, drinking normally, and hemodynamically stable before restarting, generally 48 to 72 hours post-operation (ADA/EASD consensus 2022). Check renal function (serum creatinine and eGFR) before restarting, because the perioperative period may alter GFR.

Signs That Stopping Was the Right Decision

Not every patient needs to restart. If any of these applied during treatment, the risk-benefit calculation may favor permanent discontinuation:

• Recurrent Fournier's gangrene (extremely rare but documented; FDA issued a safety communication in 2018)
• eGFR below 20 mL/min/1.73 m² with no heart failure or CKD indication
• Persistent symptomatic hypotension that limits quality of life
• Recurrent euglycemic DKA episodes despite patient education and sick-day rules

The FDA's 2018 safety communication on Fournier's gangrene across the SGLT2 inhibitor class identified 12 cases in 5 years of postmarket surveillance. The absolute risk is low. But any history of this condition is a permanent contraindication to the entire drug class.

Talking to Your Prescriber: What to Ask

Patients often stop medications without telling their physician. One survey published in JAMA Internal Medicine found that 60 percent of patients had stopped at least one chronic disease medication in the prior year without contacting their prescriber first. For empagliflozin specifically, that pattern is dangerous because of the euglycemic DKA risk and glycemic rebound.

Before your appointment, prepare answers to these questions your prescriber will need:

1. Why do you want to stop: side effect, cost, surgery, or pregnancy?
2. What is your current HbA1c and most recent eGFR?
3. What other glucose-lowering or heart-failure medications are you on?
4. Do you have a blood ketone meter at home?

A prescriber who has these answers can build a same-day discontinuation plan, including the bridge, the monitoring schedule, and the follow-up visit date.